AMENDMENTS TO THE CLAIMS

1. (Currently amended) A compound represented by the formula:

A—W—Ar (I)

wherein, A is a group represented by the formula:



wherein R^{1a} is

(1) an amino which is mono- or di-substituted with

(i) a C_{1-8} alkyl which may be substituted with a hydroxyl substituted with a C_{1-8} alkyl, a C_{3-7} cycloalkyl, a phenyl, a 4-methylphenyl, a hydroxyl substituted with a phenyl, a 2-chlorophenyl, a heterocyclic group, a 4-chlorophenyl, a 4-(benzyloxy)phenyl, a 3-methoxyphenyl, a 3-chlorophenyl, a 2'-cyanobiphenyl, a naphthyl, a 2,5-dimethoxyphenyl, a 3-fluoro-5-(trifluoromethyl)phenyl, an acyl, or an esterified or amidated carboxyl,

(ii) a C_{2-8} alkenyl,

(iii) a C_{1-10} acyl, or

(iv) a C_{3-7} cycloalkyl, or

(2) a cyclic amino;

R^2 is a hydrogen, a C_{1-8} alkyl which may be substituted by a cyano or a phenyl;

$R^{2'}$ is

(1) a hydrogen,

(2) an acetyl, or

(3) a C_{1-8} alkyl which may be substituted with a phenyl, a 4-methoxyphenyl or an acetyl;

W is a bond; and

Ar is a phenyl which is substituted with

(i) one or more C_{1-8} alkyl which may be substituted with ~~a~~ one or more halogen,

(ii) one or more alkoxy,

(iii) one or more halogen,

(iv) one or more benzyloxy, or

(v) one or more hydroxy;

or a salt thereof.

2-14. (Cancelled)

15. (Previously Presented) The compound according to claim 1, wherein the compound is 2-(dipropylamino)-5-mesityl-3,7-dimethyl-3,7-dihydro-*4H*-pyrrolo[2,3-*d*]pyrimidin-4-one.

16. (Currently Amended) A method for treating ~~or preventing~~ a disease wherein a CRF receptor is implicated, which comprises administering to a subject in need thereof an effective amount of a compound or salt according to claim 1, wherein the disease being treated ~~or prevented~~ is selected from the group consisting of affective disorder, depression and anxiety.

17. (Cancelled)

18. (Currently amended) A pharmaceutical composition comprising the compound according to claim 1 or a salt thereof, and a pharmaceutically acceptable carrier.

19-21. (Cancelled)

22. (Previously Presented) The compound according to claim 1, wherein R^{1a} is (1) an amino which is mono- or di-substituted with

(i) a C_{1-8} alkyl which may be substituted with a methoxy, a cyclopropyl, a phenyl, a 4-methylphenyl, a phenoxy, a 2-chlorophenyl, a pyridyl, a 4-chlorophenyl, a 4-(benzyloxy)phenyl, a 3-methoxyphenyl, a 3-chlorophenyl, a 2'-cyanobiphenyl, a pyrrolyl, a naphthyl, a 2,5-dimethoxyphenyl, a quinolinyl, a 3-fluoro-5-(trifluoromethyl)phenyl, a benzoyl, an ethoxycarbonyl, or an *N,N*-dimethylcarbamoyl,

(ii) a C_{2-8} alkenyl,

(iii) a C_{1-10} acyl, or

(iv) a C_{3-7} cycloalkyl,

(2) a piperidinyl,

(3) a pyrrolidinyl, or

(4) a morpholinyl.

23. (Previously Presented) The compound according to claim 1, wherein R^{1a} is an amino which is mono- or di-substituted with a C_{1-8} alkyl.

24. (Previously Presented) The compound according to claim 1, wherein R^2 is a C_{1-8} alkyl.

25. (Previously Presented) The compound according to claim 1, wherein $R^{2'}$ is a C_{1-8} alkyl.

26. (Previously Presented) The compound according to claim 1, wherein Ar is a phenyl which is substituted with one or more C_{1-8} alkyl.

27. (Previously Presented) The compound according to claim 1, wherein R^{1a} is an amino group which is mono- or di-substituted with a C_{1-8} alkyl;
R^2 is a C_{1-8} alkyl;
$R^{2'}$ is a C_{1-8} alkyl; and
Ar is a phenyl which is substituted with one or more C_{1-8} alkyl.